University of Pennsylvania Medical Center SC-4
Welcome,         Profile    Billing    Logout  
 8 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DeMichele, Angela
PALLAS, NCT02513394 / 2014-005181-30: PALbociclib CoLlaborative Adjuvant Study

Checkmark Presentation of data from PALLAS trial for ER+/HER2- breast cancer at ASCO 2022
Oct 2022 - Oct 2022: Presentation of data from PALLAS trial for ER+/HER2- breast cancer at ASCO 2022
Hourglass Jan 2021 - Jun 2021 : For early-stage breast cancer (PALLAS study)
Checkmark From PALLAS trial for HR+/HER2- breast cancer at ESMO 2020
Sep 2020 - Sep 2020: From PALLAS trial for HR+/HER2- breast cancer at ESMO 2020
More
Active, not recruiting
3
5796
Europe, Canada, Japan, US, RoW
Palbociclib, Standard Adjuvant Endocrine Therapy
Alliance Foundation Trials, LLC., Austrian Breast & Colorectal Cancer Study Group, NSABP Foundation Inc, PrECOG, LLC., Breast International Group, Pfizer
Breast Cancer
11/20
09/25
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
PALAVY, NCT04841148: Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

Recruiting
2
96
US
HCQ, Hydroxychloroquine sulfate, Plaquenil, Avelumab, MSB0010718C, Bavencio, Palbociclib, Ibrance
Abramson Cancer Center at Penn Medicine, Johns Hopkins University, Translational Breast Cancer Research Consortium, Pfizer, Breast Cancer Research Foundation
Breast Cancer
11/24
05/28

Download Options